公开(公告)号：US20180311372A1

公开(公告)日：2018-11-01

申请号：US15872841

申请日：2018-01-16

Applicant: AMGEN INC.

Inventor： Yuan CHENG ,  Chawita NETIROJJANAKUL ,  Jerry Ryan HOLDER ,  Bin WU ,  James R. FALSEY ,  Bradley J. HERBERICH ,  Kelvin SHAM ,  Leslie P. MIRANDA ,  Shu-Chen LU ,  Murielle VENIANT-ELLISON ,  Shanaka STANISLAUS ,  Junming YIE ,  Jing XU

IPC: A61K47/68 ,  C07K16/28 ,  A61P3/10

CPC classification number: C07K16/28 ,  A61K39/395 ,  A61P3/10

Abstract: Methods of treating metabolic diseases and disorders using a composition comprising an antigen binding protein specific for the GIPR polypeptide conjugated to a GLP-1 receptor agonist are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the composition comprises an antibody or functional fragment thereof comprising a cysteine at one or more conjugation site(s) wherein the GLP-1 receptor agonist is conjugated to the antibody or functional fragment thereof through the side-chain of the cysteine residue.

公开(公告)号：US20170183412A1

公开(公告)日：2017-06-29

申请号：US15400800

申请日：2017-01-06

Applicant: Amgen Inc.

Inventor： Yang LI ,  Jennitte LeAnn STEVENS ,  Chadwick Terence KING ,  Ian Nevin FOLTZ ,  Gunasekaran KANNAN ,  Junming YIE ,  Shaw-Fen Sylvia HU

IPC: C07K16/28 ,  C07K16/40

CPC classification number: C07K16/2863 ,  A61K2039/505 ,  C07K14/71 ,  C07K16/40 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/52 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/75 ,  C07K2319/00 ,  C07K2319/30 ,  C12Y302/01031

Abstract: The present invention provides compositions and methods relating to or derived from antigen binding proteins capable of inducing B-Klotho, and or FGF21-like mediated signaling. In embodiments, the antigen binding proteins specifically bind to a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c. In some embodiments the antigen binding proteins induce FGF21-like signaling. In some embodiments, an antigen binding protein is a fully human, humanized, or chimeric antibodies, binding fragments and derivatives of such antibodies, and polypeptides that specifically bind to a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c. Other embodiments provide nucleic acids encoding such antigen binding proteins, and fragments and derivatives thereof, and polypeptides, cells comprising such polynucleotides, methods of making such antigen binding proteins, and fragments and derivatives thereof, and polypeptides, and methods of using such antigen binding proteins, fragments and derivatives thereof, and polypeptides, including methods of treating or diagnosing subjects suffering from type 2 diabetes, obesity, NASH, metabolic syndrome and related disorders or conditions.

公开(公告)号：US20170275370A1

公开(公告)日：2017-09-28

申请号：US15387542

申请日：2016-12-21

Applicant: AMGEN INC.

Inventor： Junming YIE ,  Donghui SHI ,  David J. LLOYD ,  Jinghong WANG ,  Glenn N. SIVITS, JR. ,  Murielle M. VENIANT-ELLISON ,  Renee KOMOROWSKI ,  Neeraj AGRAWAL ,  Darren L. BATES ,  Brandon C. P. CLAVETTE ,  Ian N. FOLTZ ,  Shu-yin HO ,  Christopher MURAWSKY ,  Xiaoshan MIN ,  Zhulun WANG

IPC: C07K16/28 ,  A61K39/395 ,  A61K38/26 ,  A61K9/00

CPC classification number: C07K16/2869 ,  A61K9/0019 ,  A61K38/1703 ,  A61K38/26 ,  A61K39/3955 ,  A61K2039/505 ,  A61K2039/54 ,  C07K2299/00 ,  C07K2317/21 ,  C07K2317/32 ,  C07K2317/33 ,  C07K2317/41 ,  C07K2317/52 ,  C07K2317/71 ,  C07K2317/76 ,  C07K2317/92 ,  A61K2300/00

Abstract: Methods of treating metabolic diseases and disorders using an antigen binding protein specific for the GIPR polypeptide are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the antigen binding protein is administered in combination with a GLP-1 receptor agonist.

公开(公告)号：US20250121056A1

公开(公告)日：2025-04-17

申请号：US18982197

申请日：2024-12-16

Applicant: AMGEN INC.

Inventor： Yuan CHENG ,  Chawita NETIROJJANAKUL ,  Jerry Ryan HOLDER ,  Bin WU ,  James R. FALSEY ,  Bradley J. HERBERICH ,  Kelvin SHAM ,  Leslie P. MIRANDA ,  Shu-Chen LU ,  Murielle M. VENIANT-ELLISON ,  Shanaka STANISLAUS ,  Junming YIE ,  Jing XU

IPC: A61K39/395 ,  A61K47/68 ,  A61P3/10 ,  C07K16/28

Abstract: Methods of treating metabolic diseases and disorders using a composition comprising an antigen binding protein specific for the GIPR polypeptide conjugated to a GLP-1 receptor agonist are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the composition comprises an antibody or functional fragment thereof comprising a cysteine at one or more conjugation site(s) wherein the GLP-1 receptor agonist is conjugated to the antibody or functional fragment thereof through the side-chain of the cysteine residue.

公开(公告)号：US20220025059A1

公开(公告)日：2022-01-27

申请号：US17332578

申请日：2021-05-27

Applicant: AMGEN INC.

Inventor： Junming YIE ,  Donghui SHI ,  David J. LLOYD ,  Jinghong WANG ,  Glenn N. SIVITS, JR. ,  Murielle M. VENIANT-ELLISON ,  Renee KOMOROWSKI ,  Neeraj AGRAWAL ,  Darren L. BATES ,  Brandon C. P. CLAVETTE ,  Ian N. FOLTZ ,  Shu-yin HO ,  Christopher MURAWSKY ,  Xiaoshan MIN ,  Zhulun WANG

IPC: C07K16/28

Abstract: Methods of treating metabolic diseases and disorders using an antigen binding protein specific for the GIPR polypeptide are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the antigen binding protein is administered in combination with a GLP-1 receptor agonist.

公开(公告)号：US20210154318A1

公开(公告)日：2021-05-27

申请号：US17151045

申请日：2021-01-15

Applicant: Amgen Inc.

Inventor： Yuan CHENG ,  Chawita NETIROJJANAKUL ,  Jerry Ryan HOLDER ,  Bin WU ,  James R. FALSEY ,  Bradley J. HERBERICH ,  Kelvin SHAM ,  Leslie P. MIRANDA ,  Shu-Chen LU ,  Murielle VENIENT-ELLISON ,  Shanaka STANISLAUS ,  Junming YIE ,  Jing XU

IPC: A61K47/68 ,  A61P3/10 ,  C07K16/28 ,  A61K39/395

Abstract: Methods of treating metabolic diseases and disorders using a composition comprising an antigen binding protein specific for the GIPR polypeptide conjugated to a GLP-1 receptor agonist are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the composition comprises an antibody or functional fragment thereof comprising a cysteine at one or more conjugation site(s) wherein the GLP-1 receptor agonist is conjugated to the antibody or functional fragment thereof through the side-chain of the cysteine residue.

公开(公告)号：US20190248906A1

公开(公告)日：2019-08-15

申请号：US16282834

申请日：2019-02-22

Applicant: Amgen, Inc.

Inventor： Yang LI ,  Jennitte LeAnn STEVENS ,  Chadwick Terence KING ,  Ian Nevin FOLTZ ,  Gunasekaran KANNAN ,  Junming YIE ,  Shaw-Fen Sylvia HU

IPC: C07K16/28 ,  C07K14/71 ,  C07K16/40

CPC classification number: C07K16/2863 ,  A61K2039/505 ,  C07K14/71 ,  C07K16/40 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/52 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/75 ,  C07K2319/00 ,  C07K2319/30 ,  C12Y302/01031

Abstract: The present invention provides compositions and methods relating to or derived from antigen binding proteins capable of inducing B-Klotho, and or FGF21-like mediated signaling. In embodiments, the antigen binding proteins specifically bind to a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c. In some embodiments the antigen binding proteins induce FGF21-like signaling. In some embodiments, an antigen binding protein is a fully human, humanized, or chimeric antibodies, binding fragments and derivatives of such antibodies, and polypeptides that specifically bind to a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c. Other embodiments provide nucleic acids encoding such antigen binding proteins, and fragments and derivatives thereof, and polypeptides, cells comprising such polynucleotides, methods of making such antigen binding proteins, and fragments and derivatives thereof, and polypeptides, and methods of using such antigen binding proteins, fragments and derivatives thereof, and polypeptides, including methods of treating or diagnosing subjects suffering from type 2 diabetes, obesity, NASH, metabolic syndrome and related disorders or conditions.